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Background: Perioperative staging laparoscopy is a useful tool for the detection of occult peritoneal metastases in
gastrointestinal cancers. This retrospective study aimed to determine the clinical value of staging laparoscopy for
advanced or recurrent gastric cancer.
Methods: A total of 178 patients with advanced or recurred gastric cancer who underwent perioperative staging
laparoscopy were enrolled. In the absence of peritoneal deposits (P1) and positive peritoneal cytology (CY1),
gastrectomy with lymph node dissection was indicated with curative intent. If P1 or CY1 was detected
intraoperatively, patients received intensive chemotherapy and laparoscopic surgical intervention.
Results: Curative gastrectomy was performed in 104 patients after confirmation of P0 and CY0 status. P1 or CY1
was detected for the first time in 23 (15%) patients. A total of 13 patients were converted from gastrectomy to
intensive chemotherapy after detection of P1 or CY1. Additional laparoscopic interventions included insertion of
intraperitoneal reservoir port in 54 patients, insertion of a metallic stent in five, ileostomy for colon stricture in six,
jejunostomy in 19, and gastrojejunostomy in 16. Of eight patients treated with intensive chemotherapy who
underwent R0 gastrectomy after second-look laparoscopy, five are currently free from recurrence of gastric cancer
for 25.5 months.
Conclusions: Occult peritoneal dissemination was detected in about 14% in patients with tumors deeper than T2.
Moreover, additional laparoscopic interventions can be utilized for P1 or CY1 patients. The excellent surgical
outcomes of R0 gastrectomy after chemotherapy and second-look laparoscopy indicate that confirmation of P0 and
CY0 status by staging laparoscopy is of value to determine treatment strategy in patients with advanced gastric
cancer.
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Gastric cancer is one of the most common gastrointestinal
cancers in Asian countries, especially in Japan [1]. Periton-
eal dissemination (P+) is the most common type of recur-
rence in advanced gastric cancer, and gastric cancer with
serosal exposure is often associated with P + or positive cy-
tology (CY1) [2]. Once peritoneal metastases are detected,
patient outcomes are poor despite complete (R0) resection
[2-4]. The indication for cytoreductive gastrectomy in gas-
tric cancer patients without clinical symptoms such as* Correspondence: ishiga@m.kufm.kagoshima-u.ac.jp
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reproduction in any medium, provided the orbleeding, strictures or perforation has been equivocal [5].
The use of chemotherapy for advanced gastric cancer has
been stimulated by the development of new anticancer
agents, which may provide a means of improving the clin-
ical outcomes of gastric cancer patients with distant metas-
tases [6-8]. We previously reported that salvage surgery in
stage IV gastric cancer patients after intensive chemother-
apy was associated with good clinical outcomes [9]. There-
fore, detection of P1 or CY1 is an indication for intensive
chemotherapy but not R0 surgery.
Although overt dissemination or ascitic fluid can be rou-
tinely detected by preoperative abdominal CT or ultrason-
ography combined with other modalities, tiny lesions often
go undetected. The intraabdominal spread of advancedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tional laparotomy, leading to a high rate of unnecessary
laparotomies or gastrectomies [10]. Accurate tumor staging
is essential for the selection of the appropriate treatment
strategy for gastric cancer. In comparison to conventional
extracorporeal imaging technique, staging laparoscopy is an
effective and less invasive tool for the detection of unsus-
pected peritoneal metastasis. With the improvements in lap-
aroscopic instruments and techniques, gastrectomy with
lymph node dissection has become a popular procedure
among gastrointestinal surgeons [11]. These advances have
improved the accuracy of staging laparoscopy and have
enabled the detection of intra-abdominal deposits by
intraoperative pathological examination. Since June 2002,
perioperative staging laparoscopy has been used at our insti-
tution to determine whether R0 gastrectomy or less invasive
surgical intervention is indicated in patients with advanced
gastric cancer. The present study is a retrospective analysis
of the clinical outcomes of this series and a discussion of the
clinical implications of perioperative staging laparoscopy.
Methods
Patients
A total of 178 gastric cancer patients who were preopera-
tively diagnosed with tumors deeper than T2 at Kagoshima
University Hospital (Japan) were consecutively enrolled. Of
the 178 gastric cancer patients, six underwent staging lapar-
oscopy after the detection of postoperative peritoneal me-
tastases, 71 were preoperatively suspected as having distant
metastases, and the remaining 101 planned to undergo R0
gastrectomy. Type 4 tumors were diagnosed in 55 patients
(Additional file 1: Table S1). Clinicopathological features
were assessed using the Japanese Classification of Gastric
Carcinoma (JCGC, 13th edition) [12]. This research was
carried out in compliance with the Helsinki Declaration.
Staging laparoscopy indications and procedure
The indications for staging laparoscopy included sus-
pected serosal invasion of the carcinoma, the possibility
of peritoneal metastases, positive cytology or the pres-
ence of ascetic fluid. Staging laparoscopy was performed
under general anesthesia immediately before surgery. An
incision was made at the umbilicus and a 12-mm trocar
was directly introduced into the abdomen to be used as
the scope port. The second and third trocars were 5 mm
in diameter and were inserted at the right and left lower
abdominal regions and used as the working ports. The
abdominal cavity was explored systematically. First, peri-
toneal lavage was performed with 300 cc of saline for
cytological examination of the peritoneal fluid. When
the cancer cells were found in the peritoneal washing,
the patient was classified as positive cytology (CY1). The
condition of the peritoneum was examined. The bilateral
subphrenic spaces, lesser omentum and surface of thestomach, distant peritoneum including the rectouterine
pouch, and the surface of the entire bowel were first ex-
amined. Then, the omental bursa was opened and the
surfaces of the pancreas and the stomach were exam-
ined. If suspicious peritoneal nodules were detected, the
lesion was excised and processed into frozen sections for
intraoperative histological diagnosis. When the patho-
logical examination of the peritoneal nodule revealed
adenocarcinoma, the patient was diagnosed with positiv-
ity of peritoneal metastasis (P1). In patients showing P1
and/or CY1, treatment by gastrectomy was changed to
intensive chemotherapy (Figure 1). Patients with P1 and/
or CY1 were mainly treated with a combination of S-1
and paclitaxel as previously reported [13].
Treatment strategies
After confirming P0 and CY0 by staging laparoscopy, lap-
aroscopic R0 gastrectomy plus bursectomy was performed
[14]. If P1 or CY1 was identified by histological examin-
ation, gastrectomy with curative intent was discontinued
and intensive chemotherapy was indicated. Furthermore,
these patients received laparoscopic interventions to abate
the clinical symptoms of gastric cancer. When second-look
laparoscopy after intensive chemotherapy revealed neither
P1 nor CY1, R0 gastrectomy was indicated (Figure 1).
Statistical analyses
The statistical analysis of clinical features was performed
using the χ2-test. Survival curves were constructed using
the Kaplan-Meier method. A P value of <0.05 was con-
sidered significant.
Results
Rate of peritoneal metastases and positive cytology
P1 and CY1 were detected in 59 (34%) and 62 (35%) pa-
tients, respectively, according to the staging laparoscopy
results. P1 and/or CY1 were detected for the first time
in 23 patients by laparoscopy (Figure 2). A total of 13
patients were diagnosed preoperatively, and 6, 21 and 13
patients were stage II (n =3), IIIA (n =5) and IIIB (n =5),
respectively (Additional file 2: Table S2). The detection
rate of P1 and/or CY1 in stage III patients was signifi-
cantly higher than that in stage IB patients (P <0.05). P1
or CY1 was detected for the first time in 23 (15%) pa-
tients (Figure 3). Thirteen patients were converted from
gastrectomy to intensive chemotherapy after detection
of P1 or CY1.
Laparoscopic interventions for P1 and/or CY1 gastric
cancer patients
After the staging laparoscopy, various types of surgery were
performed in different patients to reduce the clinical symp-
toms using a laparoscopic approach. An intraperitoneal res-
ervoir port was inserted in 54 patients, a metallic stent was
Figure 1 Distribution of gastric cancer patients diagnosed by staging laparoscopy. After the staging laparoscopy, 178 patients were
divided into chemotherapy (n =76) and R0 gastrectomy (n =102) groups according to peritoneal dissemination and cytology status. Of 76
patients who received chemotherapy, eight underwent second-look laparoscopy and R0 gastrectomy.
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tients for stricture of the colon, and jejunostomy and gastro-
jejunostomy for alimental bypass were performed in 19 and
16 patients, respectively (Additional file 3: Table S3). The
cytological examination was repeated from the intraperito-
neal port during intensive chemotherapy.R0 gastrectomy after second-look laparoscopy following
intensive chemotherapy
A total of eight patients underwent R0 gastrectomy after P0
and CY0 were confirmed by second-look laparoscopy.
During the follow-up period of 12 to 68 months, 3 of these
patients showed peritoneal recurrence despite confirmation
of P0 and CY0 status. At present, four out of five living
patients are free from recurrence of carcinoma. All of the
patients with recurrence of the disease showed Grade 1
histological effect of the primary tumor after chemotherapy
(Additional file 4: Table S4).Figure 2 Detection of peritoneal dissemination and positive cytology
and positivity of cytology was detected in 15% (n =23) for the first time du
and 9 patients respectively.Discussion
Gastrectomy for gastric cancer is of no value in patients
with P1 and/or CY1 except as a palliative surgery to re-
duce symptoms such as bleeding and stricture [15]. On
the other hand, staging laparoscopy can be beneficial be-
cause of its high rate of detection of peritoneal metasta-
ses or positive cytology.
Song et al. showed that the overall accuracy of the P factor
was 91.7% in T3 and T4 gastric cancer [16]. Tsuchida et al.
also showed that the detection rate of P1 or CY1 by staging
laparoscopy was higher than 30% in T4 gastric cancer [17],
which is in agreement with our results. Moreover, we
showed a high positivity rate of P1 or CY1 in stage III gastric
cancer. Concerning cost-effectiveness [18], staging laparos-
copy is indicated in patients with advanced (stage III or
higher) gastric cancer.
A variety of laparoscopic interventions can be performed
during staging laparoscopy and these laparoscopic interven-
tions can especially be utilized for P1 or CY1 patients withby staging laparoscopy for the first time. Peritoneal dissemination
ring staging laparoscopy. P1, CY1 and P1CY1 were detected in 8, 6
Figure 3 Detection of peritoneal dissemination and positive cytology by staging laparoscopy for the first time.
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trojejunostomy and feeding tube insertion for gastric outlet
obstruction has been reported [19-21]. In our series, 16 pa-
tients showed good recovery with food intake after gastroje-
junostomy, and their quality of life was found to be
improved during outpatient visits.
An intraperitoneal infuser port was inserted in 59 pa-
tients for the treatment of ascitic fluid or for the adminis-
tration of anticancer agents. Furthermore, this route was
repeatedly used for cytological evaluation during the course
of chemotherapy. In fact, after confirmation of negative cy-
tology using this port, R0 gastrectomy was performed after
second-look laparoscopy.
In patients receiving intensive chemotherapy for P1 or
CY1 gastric cancer, if lesions cannot be detected by CT
or US, second-look laparoscopy should be used to esti-
mate accurate staging. The timing of the second-look
laparoscopy was generally selected based on the detec-
tion of negative cytology through the intraabdominal
port. Yano et al. showed that a second staging laparos-
copy accurately assessed the response to neoadjuvant
chemotherapy, thus helping make decisions regarding R0
gastrectomy [22]. Moreover, Ajani et al. indicated that clin-
ical staging by laparoscopy and endoscopic ultrasonography
improved R0 resection rates after chemotherapy in patients
with potentially resectable gastric carcinoma [23].
Although the surgical outcome of these patients was
fairly good, three (38%) showed postoperative peritoneal
recurrence. Pathological examination showed a poor
histological effect of chemotherapy in these three pa-
tients. As we previously reported [9], the histological
grading reflected the postoperative course of salvage
surgery in the current study. When performing R0
surgery in patients with peritoneal metastasis, P0 and
CY0 status should be confirmed by laparoscopy and thehistological grade of the chemotherapy should be
considered.
Conclusions
In conclusion, we showed the clinical usefulness of staging
laparoscopy for advanced (stage III or higher) gastric cancer
patients not only to avoid negative laparotomy, but also to
facilitate laparoscopic interventions. Second-look laparos-
copy after intensive chemotherapy is a useful tool for con-
firming the indication of R0 gastrectomy.
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